echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Detailed Nature Paper: Discovery of a new leucine receptor protein SAR1B that regulates lung cancer through mTORC1

    Detailed Nature Paper: Discovery of a new leucine receptor protein SAR1B that regulates lung cancer through mTORC1

    • Last Update: 2021-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The full name of mTOR is the mammalian target of rapamycin ( mTOR ), which plays an important role in cell life activity and metabolic regulation.


    The full name of mTOR is the mammalian target of rapamycin ( mTOR ), which plays an important role in cell life activity and metabolic regulation.


    The process of


    2021 Nian 7 Yue 21 days, the future Institute of Technology School of Molecular Medicine, Peking University, Beijing University - Tsinghua University Joint Center for Life Sciences, Beijing future genetic diagnosis -tech innovation center Liu Ying research group at diagnosisNaturepublished online entitled: Sar1b Senses Leucine A research paper on levels to regulate mTORC1 signalling.


    The study reported a novel leucine receptor protein SAR1B 's regulatory mechanism on mTORC1 , and found that SAR1B-mTORC1 signaling plays a potential role in human non-small cell lung cancer


    The study reported a novel leucine receptor protein SAR1B 's regulatory mechanism on mTORC1 , and found that SAR1B-mTORC1 signaling plays a potential role in human non-small cell lung cancer


    Research ideas and results display Research ideas and results display

    SAR1B controls leucine-dependent mTORC1 signaling

    SAR1B controls the leucine-dependent mTORC1 signal SAR1B controls the leucine-dependent mTORC1 signal

    Researchers have attempted to find more amino acid signal to pass to mTORC1 upstream regulatory factor, and found to participate in a vesicle formed G protease --SAR1B may be in the absence of an amino acid GATOR2 binding knockdown SAR1B cause mTORC1 to lack amino acid insensitive Thus, the activity continues to be maintained, and the lack of SAR1B specifically affects the regulation of leucine on mTORC1 , but has no effect on other amino acids, indicating that SAR1B may be a leucine receptor


    Researchers have attempted to find more amino acid signal to pass to mTORC1 upstream regulatory factor, and found to participate in a vesicle formed G protease --SAR1B may be in the absence of an amino acid GATOR2 binding knockdown SAR1B cause mTORC1 to lack amino acid insensitive Thus, the activity continues to be maintained, and the lack of SAR1B specifically affects the regulation of leucine on mTORC1 , but has no effect on other amino acids, indicating that SAR1B may be a leucine receptor


    Through immunoprecipitation and in vitro experiments to study the interaction between proteins and their components, the researchers concluded that when leucine is lacking, SAR1B binds to and inhibits the mTORC1 activator GATOR2 complex, inactivating mTORC1 and synthesizing Metabolism stagnates; when leucine is sufficient, SAR1B binds to leucine, undergoes a conformational change, dissociates from GATOR2 , activates mTORC1 , and initiates anabolic metabolism


    Figure 1 : SAR1B senses the level of leucine in cells and regulates mTORC1 signal through GATOR2

    Figure 1 : SAR1B senses the level of leucine in cells and regulates mTORC1 signal through GATOR2

    SAR1B and Sestrin2 are different in the perception of leucine

    SAR1B and Sestrin2 have differences in the perception of leucine SAR1B and Sestrin2 have differences in the perception of leucine

    The above experiments indicate that SAR1B and Sestrin2 may act as leucine receptors at the same time , but the two have different modes of action.


    The above experiments indicate that SAR1B and Sestrin2 may act as leucine receptors at the same time , but the two have different modes of action.


    1 ) They bind to different subunits of GATOR2 .


    2 ) Their binding affinity to leucine is different.


    3 ) They recognize different structural features of leucine


    4 ) The two receptor proteins have differences in tissue distribution, and in muscle, the two receptors coordinately regulate mTORC1 ( 2c )


    Figure 2 : The difference between SAR1B and Sestrin2 and the synergistic regulation of mTORC1 signal pattern between the two

    Figure 2 : The difference between SAR1B and Sestrin2 and the synergistic regulation of mTORC1 signal pattern between the two

    SAR1B exerts a potential inhibitory effect in human non-small cell lung cancer

    SAR1B exerts a potential inhibitory effect in human non-small cell lung cancer SAR1B exerts a potential inhibitory effect in human non-small cell lung cancer

    Human lung squamous cell carcinoma and adenocarcinoma Sar1b statistics of the number of mutations and mutation frequency display, Sar1b in human lung squamous cell carcinoma and adenocarcinoma are often missing, Further, while two human lung fibroblasts silencing SAR1B and its homologous protein SAR1A in cells ( IMR-90 and HFL1 ) eliminate leucine sensitivity and structurally activate mTORC1 .


    Human lung squamous cell carcinoma and adenocarcinoma Sar1b statistics of the number of mutations and mutation frequency display, Sar1b in human lung squamous cell carcinoma and adenocarcinoma are often missing, Further, while two human lung fibroblasts silencing SAR1B and its homologous protein SAR1A in cells ( IMR-90 and HFL1 ) eliminate leucine sensitivity and structurally activate mTORC1 .

    Therefore, the researchers proposed that the SAR1B-mTORC1 signal may play a potential role in human non-small cell lung cancer, and subsequently established a subcutaneous xenograft tumor model ( 3a ) and an orthotopic xenograft tumor model (3c) to prove this hypothesis
    .
    The study found that the lack of SAR1A and SAR1B promotes the growth of subcutaneous tumors ( 3b ), and at the same time promotes the growth of tumors in the lungs of mice ( 3d ).
    In addition, representative immunohistochemical images show that the lack of SAR1A and SAR1B can promote metabolic reprogramming in tumors ( 3e).
    ) To promote the growth and proliferation of tumors
    .
    The above experimental results indicate that SAR1B may play a potential inhibitory effect in human non-small cell lung cancer
    .

    Therefore, the researchers proposed that the SAR1B-mTORC1 signal may play a potential role in human non-small cell lung cancer, and subsequently established a subcutaneous xenograft tumor model ( 3a ) and an orthotopic xenograft tumor model (3c) to prove this hypothesis
    .
    The study found that the lack of SAR1A and SAR1B promotes the growth of subcutaneous tumors ( 3b ), and at the same time promotes the growth of tumors in the lungs of mice ( 3d ).
    In addition, representative immunohistochemical images show that the lack of SAR1A and SAR1B can promote metabolic reprogramming in tumors ( 3e).
    ) To promote the growth and proliferation of tumors
    .
    The above experimental results indicate that SAR1B may play a potential inhibitory effect in human non-small cell lung cancer
    .

    Figure 3 : SAR1B is a potential tumor suppressor in lung cancer

    Figure 3 : SAR1B is a potential tumor suppressor in lung cancer

    In summary, this study discovered a new leucine receptor protein SAR1B , and analyzed its molecular mechanism that senses leucine and regulates mTORC1 signaling through GATOR2 .
    Through bioinformatics analysis and establishment of a nude mouse orthotopic tumor model, the researchers proved that SAR1B is a potential tumor suppressor factor for human non-small cell lung cancer, and it is promising to become a new type of biomarker for non-small cell lung cancer.
    Therapies provide new drug targets .


    In summary, this study discovered a new leucine receptor protein SAR1B , and analyzed its molecular mechanism that senses leucine and regulates mTORC1 signaling through GATOR2 .
    Through bioinformatics analysis and establishment of a nude mouse orthotopic tumor model, the researchers proved that SAR1B is a potential tumor suppressor factor for human non-small cell lung cancer, and it is promising to become a new type of biomarker for non-small cell lung cancer.
    Therapies provide new drug targets .


    references:

    references:

    1.
    Robert A.
    Saxton, David M.
    Sabatini.
    .
    mTOR Signaling in Growth, Metabolism, and Disease.
    Cell 168, 960-976 (2017)

    1.
    Robert A.
    Saxton, David M.
    Sabatini.
    .
    mTOR Signaling in Growth, Metabolism, and Disease.
    Cell 168, 960-976 (2017)

    2.
    Bar-Peled, L.
    et al.
    A Tumor suppressor complex with GAP activity for the Rag GTPasesthat signal amino acid sufficiency to mTORC1.
    Science 340, 1100–1106 (2013)

    2.
    Bar-Peled, L.
    et al.
    A Tumor suppressor complex with GAP activity for the Rag GTPasesthat signal amino acid sufficiency to mTORC1.
    Science 340, 1100–1106 (2013)

    3.
    Wolfson, RL et al.
    Sestrin2 is a leucine sensor for the mTORC1 pathway.
    Science 351,43–48 (2016)

    3.
    Wolfson, RL et al.
    Sestrin2 is a leucine sensor for the mTORC1 pathway.
    Science 351,43–48 (2016)

    4.
    Zanetti, G.
    , Pahuja, KB, Studer, S.
    , Shim, S.
    & Schekman, R: COPII and the regulation of protein sorting in mammals.
    Nat.
    Cell Biol.
    14, 20–28 (2012)

    4.
    Zanetti, G.
    , Pahuja, KB, Studer, S.
    , Shim, S.
    & Schekman, R: COPII and the regulation of protein sorting in mammals.
    Nat.
    Cell Biol.
    14, 20–28 (2012)

    in This message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.